Abstract
Atrial fibrillation is the most common, serious, cardiac arrhythmia and increases the risk for ischemic stroke fivefold. Nonvalvular atrial fibrillation may be responsible for up to 15-20% of strokes. Antiplatelet agents and oral anticoagulants are used for stroke prevention in atrial fibrillation. The following review article discusses the potential risks and benefits of oral anticoagulants in nonvalvular atrial fibrillation with particular emphasis on accurate risk stratification tools for ischemic stroke.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
